je.st
news
Endocyte's ovarian cancer drug fails trial, shares sink
2014-05-04 10:59:52| Biotech - Topix.net
Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug as it failed to improve survival rates without the cancer worsening, sending Endocyte's shares tumbling as much as 63 percent.
Tags: trial
drug
cancer
shares
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||